Losartan-Induced Hepatotoxicity-Reply

JAMA: The Journal of the American Medical Association

Volumn 278, Issue 19, 1997, Pages 1572-

  Goldberg, Allan I ^a   Smith, I Sanford ^a   Stephenson, Wendy P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; HUMAN; HYPERTENSION; LETTER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030724035     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1997.03550190036038     Document Type: Letter

References (1)

1. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin-converting enzyme inhibitors. J Hypertens. 1995;13(suppl 1):577-580.